Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
Katsuyoshi Matsuoka,
Tadakazu Hisamatsu,
YOKO MURATA,
Katsumasa Nagano,
Shinya Nagasaki
Affiliations
Katsuyoshi Matsuoka
2 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan
Tadakazu Hisamatsu
7 Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan
YOKO MURATA
Medical Affairs Division, Immunology and Infectioous Disease Department, Janssen Pharmaceutical K.K, Chiyoda-ku, Japan
Katsumasa Nagano
Medical Affairs Division, Immunology and Infectioous Disease Department, Janssen Pharmaceutical K.K, Chiyoda-ku, Japan
Shinya Nagasaki
Medical Affairs Division, Immunology and Infectioous Disease Department, Janssen Pharmaceutical K.K, Chiyoda-ku, Japan
